Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Gubra reveals early data for once-weekly obesity asset
Gubra’s once-weekly obesity candidate was tied to 3% weight loss during a six-week phase 1 trial, with most adverse events "mild" and "transient."
Gabrielle Masson
Nov 13, 2024 5:56pm
Adaptimmune's cell therapy hits key goal in pivotal sarcoma test
Nov 13, 2024 2:57pm
Syros flunks phase 3 blood cancer trial, triggering loan default
Nov 13, 2024 10:00am
Hidden data on obesity prospect wipe $12B off Amgen market cap
Nov 13, 2024 6:35am
Syndax stock slips after AML drug hits midstage trial goal
Nov 12, 2024 2:00pm
After phase 2 data, Insilico plots pivotal lung disease trial
Nov 12, 2024 1:34pm
